

INDONESIAN JOURNAL OF
**CLINICAL PATHOLOGY AND
 MEDICAL LABORATORY**
 Majalah Patologi Klinik Indonesia dan Laboratorium Medik

CONTENTS

RESEARCH

Differences of Plasma Interleukin-6 and Tumor Necrosis Factor-A Levels in Healthy People, Rifampicin Resistant and Sensitive Pulmonary Tuberculosis Patients Wahyu Setiani Wibowo, Jusak Nugraha, Soedarsono	129 - 134
Association between Specific Enolase Serum Levels and Outcome Acute Ischemic Stroke One Month After Onset Yuri Haiga, Darwin Amir, Yuliarni Syafrita	135 - 139
Analysis of Hemoglobin Levels And Leukocyte Count in Neonates with Hyperbilirubinemia Dewi Suharti, Sulina Yanti Wibawa, Muthmainnah	140 - 144
Diagnostic Value of Ca-125 in Patients with Epithelial Ovarian Cancer at the Dr. Soetomo General Hospital Surabaya in 2016 Kintan P. R. Kania, Betty A. Tambunan, Willy Sandhika	145 - 149
Analysis of Vitamin D in Patients with Type 2 Diabetes Mellitus Arfandhy Sanda, Uleng Bahrun, Ruland DN. Pakasi, Andi Makbul Aman	150 - 154
Proportion of Rhesus Blood Phenotypes at the Blood Donor Unit in Bandung City Ivana Dewi, Nadjwa Zamalek Dalimoenthe, Anna Tjandrawati, Nida Suraya	155 - 160
Correlation of Total Lymphocyte Count with CD4 Count in HIV/TB Coinfected Patients Herniaty Rampo, Uleng Bahrun, Mansyur Arif	161 - 164
Using Six Sigma to Evaluate Analytical Performance of Hematology Analyzer Robiul Fuadi	165 - 169
Correlation of AA Index with Degree of Liver Fibrosis in Chronic Hepatitis B Patients Rika Andriany, Ibrahim Abdul Samad, Mansyur Arif	170 - 173
Difference in HbA1c Level between Boronate Affinity and Ion Exchange-High Performance Liquid Chromatography Method in Diabetic Patient Tuti Asryani, Ellyza Nasrul, Rikarni, Tutty Prihandani	174 - 179
Diagnostic Value of Neutrophil Lymphocyte Ratio to Differentiate Ischemic and Hemorrhagic Stroke Martina Rentauli Sihombing, Liong Boy Kurniawan, Darwati Muhadi	180 - 183
D-Dimer and Fibrinogen in Patients Underwent Surgery in Malignant and Benign Ovarian Tumor Ismail Aswin, Herman Hariman, Fauzie Sahil	184 - 190

Relationship between Specific Gravity of Cupric Sulfate and Saturation of Blood Droplets During Donor's Hemoglobin Screening Resna Hermawati, Solichul Hadi	191 - 193
Vancomycin-Resistant <i>Staphylococcus aureus</i> at the Dr. Wahidin Sudirohusodo Hospital Makassar Fatmawaty Ahmad, Nurhayana Sennang, Benny Rusli	194 - 198
The Levels of Interleucin-6 (IL-6) and Tumor Necrosis Factor Alpha (TNF-ALFA) in Preeclampsia Patient and Normal Pregnancy Mawardi, Ratna Akbari Ganie, Sarma N. Lumbanraja	199 - 201
Analysis of Platelet Volume Mean, Platelet Distribution Width, and Platelet Count in Hemorrhagic and Non-Hemorrhagic Stroke Gita Medita Sunusi, Darwati Muhadi, Mansyur Arif	202 - 206
High Fluorescent Lymphocyte Count Examination in Dengue Hemorrhagic Patients with Sysmex Xn-1000 Hematology Analyzer Budiono Raharjo, Solichul Hadi	207 -210
Prevalence and Characteristics of Multidrug-Resistant <i>Acinetobacter baumannii</i> Cases at the Dr. Wahidin Sudirohusodo General Hospital in Makassar Dewi Kartika Tungadi, Nurhayana Sennang, Benny Rusli	211 - 217
The Correlation of Anemia and Hcpidin Serum Levels in Regular Hemodialysis Patients with Chronic Hepatitis C Wingsar Indrawanto, Adi Koesoema Aman, Alwi Thamrin	218 - 223
The Comparison between HbA1c and Glycated Albumin Level Patient with Type II Diabetes Mellitus with or without CKD M. Rusli, Zulfikar, Santi Syafril	224 - 227
Differentiation of $T\gamma\delta$ Lymphocyte Cells Expressing Interleukin-17 on Healthy Persons and Adult Acute Myeloid Leukemia Patients Elvan Dwi Widyadi, Yetti Hernaningsih, Endang Retnowati, Ugroseno, Ryzky Widi Atmaja	228 - 232

LITERATURE REVIEW

Hormone Examination in Menopause Ferdy Royland Marpaung, Trieva Verawaty Butarbutar, Sidarti Soehita	233 - 239
--	-----------

CASE REPORT

Chronic Myelogeneous Leukemia Transformation into Acute Lymphoblastic Leukemia Endah Indriastuti, Arifoel Hajat	240 - 245
Rapid Progression of Clavicular Solitary Plasmacytoma to Multiple Myeloma Hantoro Gunawan, Paulus Budiono Notopuro	246 - 249

USING SIX SIGMA TO EVALUATE ANALYTICAL PERFORMANCE OF HEMATOLOGY ANALYZER

Robiul Fuadi

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital Surabaya, Indonesia.
E-mail: robiul.fuadi@yahoo.com

ABSTRACT

Many medical decisions in the hospital based on hematology examination results, must be aware of their method performance. Sigma-metric is an excellent way to evaluate analytical performance quality. The performance analysis of laboratory hematology analyzer and Cell Dyne Ruby can use Sigma-metric. This study aimed to evaluate the analytical performance of Abbott Cell Dyne Ruby hematology analyzer, by Six Sigma in Clinical Pathology Laboratory of the Dr. Soetomo Hospital Surabaya, Indonesia. Sigma analysis was calculated by a formula, $\sigma = (TEa - CV) / \text{Bias}$. The CLIA proficiency testing criteria specified Total Error Allowable (TEa). The Coefficient of Variant (CV) and bias data were supplied from analyzer running three levels of control Low (L), Normal (N), and High (H) include following analytes: hemoglobin (Hb), Red Blood Cell count (RBC), Hematocrit (HCT), White Blood Cell count (WBC), and Platelet count (PLT). Sigma-value as follows Hb(L:4.33 N:6.68 H:2.62), RBC(L:3.43 N:3.84 H:3.46), HCT(L:2.52 N:1.73 H:2.27), WBC (L:7.14 N:8.44 H:6.38), and PLT (L:2.46 N:8.75 H:7.84). Average Sigma-value for all parameters was 4.75. Minimum Sigma-value for any business or manufacturing process was three. More than Six Sigma-value was a world-class performance. Hematology analyzer Cell Dyne Ruby provides "Good" performance by Sigma-metric.

Key words: Sigma-metric, cell dyne ruby, total error allowable, the coefficient of variant, bias

INTRODUCTION

Many medical decisions are based on clinical laboratory results. These include admission, discharge, even therapies such as transfusion, medication, radiotherapy, chemotherapy, and operation procedure. Almost 60-70% important medical decisions need these, to diminish laboratory error to minimize medical error.^{1,2}

There are three classic phases in laboratory process: pre-analytical, analytical, and post-analytical phase. Errors could happen in any stage of the process. Many studies show that most frequent errors occur in the pre-analytical phase.^{2,3} Errors rarely happen in the analytical phase. Automation, improved laboratory technology, assay standardization, and better-trained staff have a significant role in this. But errors can occur due to minimal internal quality control that is applied by laboratories. This phenomenon is just like an iceberg. Not many errors can be detected by minimal quality control procedure.⁴

Analytical performance is evaluated by internal and external quality assessment. Internal laboratory quality can be assessed by calculating the coefficient

of a variant that expresses the precision of each quantitative laboratory parameter. External laboratory quality for quantitative parameters can be assessed by calculating variant index score in laboratory external quality program. By Six Sigma, it will optimize statistical control rule for individual assays based on their inherent quality (bias and precision) and the accuracy required for their intended clinical use.⁵⁻⁷

Six Sigma is a quality indicator that can be used to evaluate a process. It was first described by Motorola company in the 1980s. Implementation of Six Sigma has expanded in many manufacturers, especially in flight industries where safety is their priority. Recently, many laboratories apply Six Sigma as a quality indicator in their process. Laboratories can improve quality system and especially improve patient safety by using Six Sigma.⁸⁻¹¹

Hematology analyzer is an automatic instrument to perform a Complete Blood Count (CBC) test. This examination includes counts number of hematology cells: erythrocyte, leukocyte, and platelet measures hemoglobin and hematocrit level, and also identify differential leukocyte numbers in absolute and percentage. The instrument also counts many other

parameters related to blood cells.^{12,13} CBC is one of the most frequent laboratory tests that been requested in the hospital. It can be used for screening, diagnosis, and therapy monitoring for many diseases like anemia, infectious disease, hematologic malignancy or coagulation disorder.

The laboratory must ensure that instrument for laboratory test has good quality, including hematology analyzer. It must be avoided inaccurate laboratory result that can harm patients. This study aims to evaluate the analytical performance of Abbott Cell Dyne Ruby hematology analyzer, by Six Sigma in Clinical Pathology Laboratory of the Dr. Soetomo Hospital Surabaya, Indonesia.

METHODS

Data were analyzed from the routine CBC test results of assayed control material in July-August 2016. There were three control materials: Low, Normal, and High. Examination of the material was performed once daily with Abbot Cell Dyne Ruby hematology analyzer. Hemoglobin (Hb), Hematocrit (HCT), Red Blood Cell (RBC) Count, White Blood Cell (WBC) Count, and platelet (PLT) count were analyzed in CBC results. Data was consecutively collected in one lot number, that means it has the same control material.

Mean and standard deviation of the collected data were calculated with Microsoft Excel Software. The Coefficient of Variant (CV) was calculated with the formula:

$$(SD/Mean) \times 100\%$$

Data from the mean of control material results and the target value of control material to calculate the bias was used. The value was available in the insert kit. Bias was calculated with the formula:

$$\Delta \text{ calculated mean and target value difference/target value} \times 100\%$$

Total error allowance (TEa) of each parameter was adopted from Clinical Laboratory Improvement Amendments (CLIA) criteria. Then, Sigma-value was calculated in each parameter and each control level with the formula:

$$[(TEa - Bias)/CV] \times 100\%$$

CV, Bias, and Sigma calculation were performed with Microsoft Excel Software.

RESULT AND DISCUSSION

Researchers collected 42 control material CBC test results for 42 consecutive days by Abbott Cell Dyne Ruby hematology analyzer. There were three levels of controls with different values. It was low, normal, and high. Mean, SD, and the target value of material control are available in Table 1.

Bias and CV-value were calculated from data in Table 1. Sigma-value calculated from TEa form (CLIA criteria). Data of Sigma-value, Bias, CV, and TEa were available in Table 2.

The highest Sigma-value was achieved by platelet parameter in normal level (8.74789). Hematocrit at normal level was the lowest Sigma-value (1.727522). Parameters with Sigma-value more than six were

Table 1. The target value, mean, and SD of hematology control material CBC test

Parameter	Control material	Target value	Mean	SD
Hb (g/dL)	Low	7.6	7.37	0.079373
	Normal	12.2	12.03333	0.101653
	High	15.9	15.65714	0.327981
RBC (x 10⁶/μL)	Low	2.91	2.940952	0.042415
	Normal	4.36	4.343333	0.063587
	High	5.34	5.359048	0.087459
Hematocrit (%)	Low	20.9	20.74286	0.436545
	Normal	33.2	32.37143	0.655853
	High	42.2	41.6619	0.865723
WBC (x 10³/μL)	Low	4	4.002381	0.08372
	Normal	7.2	7.304286	0.117199
	High	17.1	17.0619	0.395571
Platelet (x 10³/μL)	Low	74	82.79048	4.417002
	Normal	221	222.0952	6.220167
	High	528	507.1429	13.60987

Table 2. CV, Bias,TEa and Sigma-value

Parameter	Control material	CV (%)	Bias (%)	TEa (%) : CLIA	Sigma-value
Hb	Low	1.076968	3.02	7	3.69556
	Normal	0.844762	1.36	7	6.676438
	High	2.094768	1,52	7	2.616041
RBC	Low	1.442226	1.06	6	3.425261
	Normal	1.464019	0.38	6	3.838749
	High	1.631985	0.35	6	3.462042
Hematocrit	Low	1.442226	1.06	6	3.425261
	Normal	2.026024	2.5	6	1.727522
	High	2.077973	1.28	6	2.271445
WBC	Low	2.091756	0.06	15	7.142323
	Normal	1.60453	1.45	15	8.44484
	High	2.318444	0.2	15	6.383592
Platelet	Low	5.335157	11.8	25	2.459159
	Normal	2.800675	0.5	25	8.74789
	High	2.683636	3.95	25	7.843835

achieved by hemoglobin in normal level (6.676438), WBC at low level (7.142323), normal level (8.74789), and high level (6.383592). Sigma-value less than three were hemoglobin at high level (2.616041), platelet in low level (2.459159), hematocrit in normal level (1.727522), and high level (2.271445)

Average Sigma-value for Hb: 4.329346, HCT: 2.474743, RBC: 3.575351, WBC : 7.323585, and PLT: 6.350295. Average Sigma for all parameters and all levels was 4.75. Minimum Sigma-value for any business or manufacturing process was three. More than Six Sigma-value was a world-class performance. There are some levels related to Sigma-value in clinical laboratory practice. The levels are world-class, excellent, good, marginal, weak, and unacceptable.¹¹ The relation between the levels and Sigma-value can be seen in Table 3. Higher Sigma-value could be achieved, and fewer defect opportunities could happen.^{8,9}

Table 3. Sigma-value and the levels^{9,14}

Sigma-value	Level	Defect per million opportunities
6	World-class	3.4
5	Excellent	233
4	Good	6,210
3	Marginal	66,807
2	Poor	308,537
1	Unacceptable	690,000

More than Six Sigma-value is world-class, and minimum Sigma-value for manufacturing is three.

There are two methods to implement Sigma-metric in clinical laboratory process: For pre-analytical and post-analytical phase: numbers of defects in a group were counted, then calculate defects per million. The standard table was utilized to convert defect per

million in Sigma-value; For analytical phase: estimate imprecision and bias of the parameter performance and also define tolerance limit as total error allowance. Then we calculate Sigma-value by the formula.⁸

Imprecision is also called as the CV. Calculation of CV is based on control material test results data for the internal quality control process. Mean and SD is calculated by those data, and CV is calculated by the formula: SD/mean. Data of control material test results can be obtained by a cumulative CV from historical imprecision. Clinical & Laboratory Standards Institute (CLSI) recommends the data is obtained at least by 3-6 months routine internal quality control test; 20 days control test results that were performed twice daily; Two examination runs within a single day, each run consisting of 10-20 replicates control material. This process is also called as within-day or between-run imprecision; A single run with at least 20 replicates of control material. This process usually called as within-run imprecision or repeatability.¹⁵

In this study, data from daily control material examination for 42 consecutive days, were obtained and choose this method following our laboratory policy to perform control material test.

There are many methods to calculate bias. Data of bias can be obtained from reference material or reference method; The mean of a peer group; The all method means of a proficiency testing or external quality assessment survey; A comparative method.¹⁵ This study, used bias from the mean of a peer group from data in the kit insert of control material. This method is the easiest way if use assayed control material.

The quality requirement is expressed by TEa in Sigma-metric. This data obtain by U.S. CLIA proficiency testing criteria, the Royal College of




Figure 1. Normalized OPSspecs chart

Pathologists of Australasia (RCPA) guidelines, the Ricos *et al.* database on desirable specifications for total error based on within-subject biologic variation, an International Organization for Standardization (ISO) standard, a peer group specification, or even a locally determined specification.¹⁵

The design internal quality control procedure by Sigma-value so, need a normalized OPSspecs chart.

Data for TE_a, CV, and bias must be obtained first to use normalized OPSspecs chart. Choose normalized OPSspecs charts, start with 90% Analytical Quality Assurance (AQA) and less control material numbers (N). In hematology analyzer control materials are usually available in three numbers, low, normal, and high. Whereas in clinical chemistry, it is usually available in two numbers, normal and abnormal. Then, select a control rule(s) whose operating limits are above your normalized operating point. Identify the control rule(s) from the key on the right side of the chart. If no QC procedure can be selected, try the 90% AQA & N=6 chart. Continue with 50% AQA & N=3 Chart and 50% AQA & N=6 Chart. Choose quality control (QC) procedures can be selected.⁷

In Figure 1, 1_{3.5s} rule for WBC and 1_{3s} for RBC can be selected. Considering medical decision levels for Hb are low and normal, a 1_{3s} rule can be chosen. It is ironic for PLT count, because it has less performance in low value, whereas it has world-class performance

in high and normal value. Platelet count is important in low level because many medical decisions depend on it, especially in dengue infection disease and hemostatic disorders.¹⁴ Multi-rules of 1_{3s}/2of3_{2s}/R_{4s}/3_{1s}/6_x can be chosen for PLT QC procedure.¹⁶ Special attention must be given in HCT parameter because it has the worst Sigma-value. For now, multi-rules of 1_{3s}/2of3_{2s}/R_{4s}/3_{1s}/6_x must be chosen. The laboratory management must discuss with the instrument technician to improve HCT performance. QC procedure for the instrument is performed with 6 numbers control materials and a single run. Alternatively laboratory can use the rules with three numbers controls and double runs.¹⁷

The HCT is calculated from the RBC count and the Mean Cell Volume (MCV). The optical channel is used for the determination of RBC and PLT data. The RBC parameters are calculated using 0°, 10°, and 90° sensor data, while the PLT parameters are calculated using 0° and 10° sensor data. The MCV is derived from the RBC size distribution data on the 0°, 10°, and 90° histograms. The optical channel evaluation, especially by 90° sensor data replacement maybe can improve the Sigma-value of HCT and RBC of this instrument.¹⁸

CONCLUSION AND SUGGESTION

Sigma-metric can be used to evaluate the analytical performance of the laboratory instrument

and choose QC procedure. Cell Dyne Ruby hematology analyzer provides "Good" performance. QC procedure for the instrument is performed with multi-rule and a single run six numbers control materials or double runs three numbers control. Sigma value HCT and RBC parameters should be improved by optical channel evaluation.

REFERENCES

1. Plebani M. Errors in clinical laboratories or errors in laboratory medicine?. *Clin Chem Lab Med.* 2006; 44(6): 750–759.
2. Hammerling JA. A review of medical errors in laboratory diagnostics and where we are today. *Laboratory Medicine.* 2012; 43(2): 41-44.
3. Tiwari E, Pallipady A, Mishra S. Preanalytical, analytical and Post-analytical errors in a chemical laboratory. *International Journal of Science and Research.* 2015; 4(3): 2279-2281.
4. Plebani M. The detection and prevention of error in laboratory medicine, review article. *Ann Clin Biochem.* 2010; 47: 101–110.
5. Karkalousos P & Evangelopolous A. Quality control in clinical laboratories (internet). In *Tech Europe.* 2011(cited 30 August 2018). Available from <http://www.intechopen.com/books/applications-and-experiences-of-quality-control/quality-control-in-clinical-laboratories>.
6. Yadav R, Bhartiya JP, Verma SK, Nandkeoliar MK. External quality assessment scheme. *IJRRMS,* 2013; 3(4):1-4.
7. Westgard J & Westgard O. Six Sigma based quality control: Learning guide series. Abbott Laboratories, 2016.
8. Sawalakhe P, Desmukh S, Lakhe R. Evaluating performance of testing laboratory using Six Sigma. *International Journal of Innovations in Engineering and Science.* 2016; 1(1): 13-20.
9. Kalra J, Kopargaonkar A. Quality improvement in clinical laboratories: A Six Sigma concept. *Pathology and Laboratory Medicine,* 2016; 1(1): 11-20.
10. Maksane S, Parikh R, Vaswani L. Quantitative assessment of analytical phase quality of clinical biochemistry parameters using Sigma-metrics. *International Journal of Medical Laboratory,* 2017; 4(2): 81-90.
11. Al Muhareb TM, Jones JG. Using lean Six Sigma in the improvement of service quality at aviation industry: A case study at the departure area in KKIA. *World Academy of Science, Engineering and Technology International Journal of Environmental and Ecological Engineering,* 2014; 8(1): 145-151.
12. Turgeon M. Instrumentation in hematology in clinical hematology theory and procedure. Philadelphia USA, Lippincott Williams & Wilkins, 2012; 526-571.
13. Vajpayee N, Graham S, Bem S. Basic examination of blood and bone marrow. In Mcpherson RA, Pincus MR, editors. *Henry's clinical diagnosis and management by laboratory method.* Philadelphia USA, Elsevier Saunders, 2011; 509-535.
14. Westgard S. Six Sigma: Laboratory quality control in the healthcare ecosystem. Abbott Laboratories, 2016.
15. Westgard S. Quantitating quality: Best practices for estimating the Sigma-metric. Abbott Laboratories, 2016.
16. Deen J, Luum L, Martinez E, Huat Tan L. Clinical management and delivery of clinical services. In: Farrar J, Castelo Branco I, Dimaano E, Harris E, Hung N, Laksono IS, Martinez J, Pleites EB, Venancio R, Villegas E, Weber M, Wills B, advisers, and peer reviewers. *Dengue: Guidelines for diagnosis, treatment, prevention, and control.* France, WHO, 2009; 25-54.
17. Westgard J. Westgard rules and Multi rules (internet) Westgard rules. 2018 (cited 30 August 2018) available from website <https://www.westgard.com/mltirule.htm>
18. Abbott Laboratories. CELL-DYN Ruby TM system operator's manual. Abbott Park (USA). 2006.